pdvac
establish
depart
immun
vaccin
biolog
ivb
follow
review
process
strateg
prioriti
set
vaccin
need
group
advis
specif
vaccin
product
develop
highlight
acceler
vaccin
avail
ensur
access
vaccin
low
middl
incom
countri
lmic
pdvac
remit
advis
product
develop
strategi
vaccin
candid
phase
ii
clinic
evalu
earlier
report
proceed
princip
committe
immun
polici
recommend
strateg
advisori
group
expert
immun
sage
pdvac
committe
critic
role
assess
evolv
vaccin
develop
landscap
help
defin
impact
accord
three
criteria
likelihood
product
emerg
pipelin
defin
probabl
technic
regulatori
success
extent
awar
activ
invest
given
area
clear
role
perceiv
ad
valu
engag
pathogen
area
typic
engag
pathogen
area
work
broad
set
key
vaccin
develop
stakehold
develop
consensu
pivot
clinic
trial
design
vaccin
roadmap
guidanc
document
desir
vaccin
properti
refer
prefer
product
characterist
ppc
ppc
defin
prefer
properti
vaccin
use
lmic
year
licensur
inform
target
product
profil
use
manufactur
funder
vaccin
pdvac
also
encourag
develop
awar
process
requir
prequalif
pq
prequalif
servic
unicef
un
agenc
purchas
vaccin
licens
determin
accept
principl
vaccin
differ
sourc
suppli
agenc
aim
ensur
diagnost
medicin
vaccin
immunizationrel
equip
devic
high
burden
diseas
meet
global
standard
qualiti
safeti
efficaci
appropri
use
lmic
context
order
optim
potenti
benefit
intervent
third
pdvac
meet
held
geneva
june
dr
jeanmari
okwobel
director
ivb
open
proceed
synopsi
signific
mileston
vaccin
develop
nine
month
sinc
previou
meet
septemb
first
dengu
malaria
vaccin
licens
achiev
equival
licensur
respect
first
rsv
vaccin
candid
enter
phase
iii
studi
elderli
pregnant
women
advanc
hiv
vaccin
candid
met
endpoint
interim
analysi
phase
ii
studi
prepar
commenc
efficaci
studi
underway
conven
merscoronaviru
r
commun
phase
clinic
studi
underway
ebola
viru
vaccin
review
progress
point
consider
licensur
record
time
coordin
effort
develop
zika
viru
vaccin
expediti
possibl
pdvac
work
group
overseen
develop
zika
viru
vaccin
target
product
profil
tpp
develop
regulatori
consider
toward
phase
emerg
use
author
addit
signific
advanc
vaccin
develop
uk
govern
publish
may
report
tackl
drugresist
infect
global
commiss
collabor
welcom
trust
report
highlight
urgent
need
reduc
relianc
current
avail
antimicrobi
without
today
death
per
year
drug
resist
microb
forecast
increas
million
cost
term
lost
global
product
due
infect
control
due
antimicrobi
resist
amr
estim
trillion
action
taken
develop
vaccin
pathogen
current
control
antimicrobi
becom
imper
potenti
reduc
preval
spread
drug
resist
well
reduc
use
antimicrobi
broadli
decad
vaccin
global
vaccin
action
plan
gvap
midterm
review
requir
assess
progress
object
sinc
incept
strateg
plan
achiev
state
target
within
remain
year
part
pdvac
remit
review
vaccin
develop
pipelin
consid
prioriti
activ
ivb
within
context
remain
timefram
gvap
number
vaccin
could
reach
licensur
need
ensur
earli
engag
polici
maker
regard
potenti
vaccin
implement
well
align
gavi
vaccin
invest
strategi
facilit
inform
share
track
progress
within
global
vaccin
develop
commun
establish
maintain
onlin
vaccin
pipelin
tracker
inform
regard
current
clinic
studi
sever
differ
pathogen
area
found
addit
landscap
analys
pathogen
meet
collat
within
special
issu
journal
vaccin
avail
open
access
document
author
independ
subject
matter
expert
review
statu
vaccin
candid
develop
well
assess
possibl
pathway
regulatori
approv
pdvac
report
progress
global
vaccin
develop
pipelin
strateg
advisori
group
expert
sage
immun
meet
april
advanc
develop
intervent
vaccin
monoclon
antibodi
respiratori
syncyti
viru
rsv
present
inform
report
octob
april
sage
meet
avail
onlin
much
discuss
focus
need
better
understand
key
factor
earli
implement
well
safeti
efficaci
data
support
assess
vaccin
polici
recommend
emerg
vaccin
like
requir
new
vaccin
platform
matern
immun
visit
outsid
current
vaccin
schedul
recent
licens
malaria
vaccin
rt
costeffect
data
inform
optim
use
potenti
impact
must
gener
line
convent
clinic
data
requir
regulatori
approv
minimis
delay
vaccin
licensur
uptak
goal
third
pdvac
meet
revisit
pathogen
area
signific
progress
report
sinc
recommend
meet
well
review
statu
vaccin
develop
new
pathogen
area
signific
vaccin
develop
progress
signific
diseas
burden
r
stall
refin
workplan
strateg
direct
ivb
specif
pathogen
area
identifi
crosscut
issu
acceler
vaccin
develop
prepar
polici
decis
appropri
consid
better
align
pdvac
vaccin
develop
activ
strategi
area
research
inform
vaccin
develop
commun
regard
step
consid
beyond
vaccin
licensur
process
vaccin
polici
recommend
gvap
strateg
framework
deriv
decad
vaccin
collabor
prevent
million
death
equit
access
exist
vaccin
peopl
commun
within
framework
specif
object
support
research
develop
innov
maximis
benefit
immun
indic
progress
toward
develop
hiv
malaria
tuberculosi
influenza
vaccin
gvap
complet
midterm
review
stage
follow
recommend
sage
gvap
assess
highlight
advanc
made
area
four
pathogen
area
stand
agenda
item
discuss
pdvac
mycobacterium
tuberculosi
mtb
kill
million
peopl
million
coinfect
hiv
world
deadli
infecti
diseas
approxim
casesannum
multidrug
resist
mdr
extens
drug
resist
xdr
strain
untreat
six
million
new
case
mtb
report
fewer
twothird
million
peopl
estim
contract
diseas
mean
new
case
detect
report
vaccin
imper
achiev
end
tb
goal
particularli
reach
popul
undiagnos
continu
transmit
diseas
tb
vaccin
develop
commun
turn
focu
develop
vaccin
target
adolesc
adult
agegroup
highest
burden
activ
diseas
sourc
mtb
transmiss
model
studi
suggest
prevent
pulmonari
diseas
popul
primari
infect
reinfect
reactiv
exist
infect
effect
strategi
prevent
mtb
infect
diseas
infant
children
advanc
vaccin
candid
target
indic
includ
current
neonat
bcg
replac
candid
vaccin
also
undergo
evalu
booster
later
life
sever
candid
proofofconcept
clinic
studi
approach
key
endpoint
prevent
infect
diseas
prevent
diseas
due
reinfect
target
popul
next
month
mind
pdvac
recommend
priorit
facilit
consensu
build
respect
develop
strateg
goal
ppc
vaccin
target
adolesc
adult
first
instanc
sever
candid
platform
pipelin
target
goal
popul
well
import
target
popul
pdvac
acknowledg
signific
need
develop
vaccin
parallel
well
continu
effort
understand
biolog
mechan
diseas
support
immunolog
ration
candid
poxprotein
public
privat
partnership
consist
sanofi
glaxosmithklin
gsk
bill
melinda
gate
foundat
us
militari
hiv
research
program
mhrp
hiv
vaccin
trial
network
hvtn
collabor
us
nation
institut
allergi
infecti
diseas
niaid
optim
assess
efficaci
alvacheterolog
prime
boost
approach
follow
demonstr
partial
efficaci
trial
thailand
interim
data
phase
ii
studi
hvtn
met
humor
cellular
immunolog
go
criteria
exceed
respons
subsaharan
clade
c
antigen
extrapol
respons
observ
suggest
optimis
vaccin
could
offer
least
protect
follow
month
booster
base
data
randomis
placebo
control
phase
iibiii
efficaci
trial
enrol
subject
initi
late
south
africa
evalu
alvac
clade
c
prime
bival
recombin
protein
adjuv
heterolog
boost
well
effect
booster
month
futil
analys
undertaken
earli
year
followup
period
correl
protect
studi
assess
crossreact
region
clade
includ
studi
design
discuss
south
african
medicin
control
council
mcc
ongo
licensur
south
africa
could
earli
vaccin
candid
develop
includ
janssen
heterolog
prime
boost
approach
current
undergo
dose
regimen
select
phase
iiia
trial
antibodymedi
prevent
use
broadli
neutral
potent
monoclon
antibodi
bnmab
approach
also
undergo
phase
iiia
clinic
evalu
niaidvaccin
research
centr
broadli
neutralis
mab
advanc
candid
shown
neutralis
bind
viral
isol
hvtn
hvtn
phase
iib
studi
evalu
efficaci
reduc
acquisit
infect
high
risk
popul
america
subsaharan
africa
start
enrol
shown
effect
administr
could
posit
longact
supplement
increas
effect
antiretrovir
pdvac
commend
advanc
hiv
vaccin
develop
request
kept
inform
progress
current
known
intent
global
studi
candid
vaccin
seek
prequalif
pdvac
encourag
partner
south
african
hiv
vaccin
develop
commun
keep
fulli
inform
progress
trial
concern
express
regard
lack
followon
studi
thailand
given
initi
landmark
trial
perform
despit
substanti
reduct
last
year
global
malaria
mortal
children
age
year
mainli
due
greater
invest
malaria
control
estim
million
malaria
case
africa
peopl
die
diseas
resid
africa
given
increas
multidrug
insecticid
resist
remain
urgent
need
vaccin
combat
malaria
report
pdvac
meet
summari
european
medicin
agenc
ema
provid
posit
scientif
opinion
indic
favor
assess
riskbenefit
balanc
rt
regulatori
perspect
octob
two
advisori
bodi
name
sage
malaria
polici
advisori
committe
mpac
recommend
pilot
implement
studi
schedul
rt
vaccin
distinct
epidemiolog
set
subsaharan
africa
subnat
level
cover
moderatetohigh
transmiss
set
three
dose
administ
children
month
age
follow
fourth
dose
month
later
intent
pilot
studi
assess
feasibl
provid
four
dose
rt
target
age
group
exist
health
servic
impact
rt
child
mortal
whether
safeti
issu
particularli
evid
causal
relationship
rt
administr
either
mening
cerebr
malaria
signal
phase
iii
trial
whether
introduct
vaccin
impact
posit
neg
exist
countri
immun
program
use
current
recommend
malaria
control
measur
malaria
vaccin
technolog
roadmap
updat
includ
licensur
vaccin
target
plasmodium
falciparum
plasmodium
vivax
protect
efficaci
least
clinic
malaria
reduc
transmiss
parasit
therebi
substanti
reduc
incid
human
malaria
parasit
infect
vaccin
candid
pipelin
robust
includ
novel
antigen
platform
second
gener
vaccin
expect
provid
higher
protect
rt
longer
term
optimis
tool
need
measur
increment
improv
predict
potenti
cost
effect
new
candid
develop
control
human
malaria
infect
chmi
model
effort
harmon
element
clinic
trial
design
standard
variou
assay
continu
pdvac
stress
import
develop
gener
malaria
vaccin
parallel
pilot
implement
program
rt
propos
current
version
vaccin
roadmap
updat
potenti
light
rt
pilot
implement
pdvac
note
develop
univers
influenza
vaccin
challeng
protract
particularli
due
lack
regulatori
pathway
novel
antigen
oper
induct
tcell
immun
rather
pdvac
recommend
focu
definit
collect
data
support
implement
improv
season
flu
vaccin
would
offer
immedi
impact
lmic
pdvac
advis
develop
strateg
public
health
goal
ppc
improv
season
influenza
vaccin
provid
guidanc
data
requir
would
need
establish
improv
perform
vaccin
work
group
establish
propos
draft
statement
unmet
public
health
need
safe
welltoler
influenza
vaccin
effect
prevent
sever
influenza
ill
provid
protect
beyond
singl
year
programmat
suitabl
use
need
lowand
middleincom
countri
draft
strateg
goal
develop
influenza
vaccin
induc
broader
durabl
protect
sever
ill
caus
influenza
strain
develop
strateg
goal
draft
ppc
nextgener
influenza
vaccin
present
upcom
eighth
meet
develop
influenza
vaccin
pdvac
reaffirm
valu
ppc
base
two
differ
approach
public
health
need
develop
improv
perform
current
avail
season
vaccin
offer
protect
multipl
season
drift
strain
view
gener
shorter
timelin
achiev
avail
access
lmic
part
effort
necessari
defin
criteria
need
demonstr
clinic
benefit
addit
data
requir
support
polici
recommend
effort
develop
univers
vaccin
target
conserv
antigen
conserv
compon
antigen
continu
parallel
focu
identifi
correl
protect
support
regulatori
pathway
novel
class
vaccin
diarrheal
diseas
remain
second
lead
caus
death
children
year
age
although
mortal
declin
past
four
decad
morbid
declin
significantli
despit
improv
water
sanit
benefit
oral
rehydr
therapi
nearli
billion
case
diarrheal
diseas
everi
year
mani
acut
chronic
effect
growth
stunt
cognit
impair
long
term
sequela
significantli
impact
qualiti
life
econom
potenti
estim
affect
onefifth
children
global
pdvac
recommend
expand
remit
includ
support
enter
vaccin
develop
particularli
enterotoxigen
escherichia
coli
etec
shigella
one
main
object
plan
engag
area
ensur
design
phase
iii
efficaci
studi
includ
definit
primarysecondari
endpoint
longterm
follow
data
gener
relev
support
polici
recommend
sage
anoth
key
object
develop
prefer
product
characterist
document
outlin
prefer
includ
consider
develop
toward
potenti
combin
vaccin
sever
vaccin
develop
two
etec
candid
seven
shigella
candid
current
clinic
studi
etec
advanc
vaccin
etvax
adjuv
dmlt
develop
pediatr
travel
indic
phase
iii
dose
escal
age
deescal
studi
children
current
ongo
bangladesh
intent
age
deescal
weekold
infant
late
parallel
phase
iib
studi
travel
plan
begin
base
encourag
phase
iib
immun
challeng
studi
addit
posit
protect
studi
nonhuman
primat
nhp
adhesinbas
subunit
etec
vaccin
fta
move
forward
acceler
clinic
program
design
move
complet
multival
vaccin
descend
age
field
trial
advanc
shigella
candid
trival
shigella
kill
whole
cell
tswc
compos
formalininactiv
flexneri
flexneri
sonnei
expect
offer
coverag
across
isol
phase
studi
complet
challeng
trial
flexneri
prototyp
begin
follow
studi
assess
coadministr
etvax
etvax
tswc
develop
oral
administr
promis
shigella
vaccin
earli
stage
clinic
test
includ
two
live
attenu
vaccin
shigetec
descend
age
studi
bangladesh
shigetec
combin
shigellaetec
combin
vaccin
begin
phase
studi
earli
three
subunit
approach
shigella
also
phase
iii
studi
prototyp
flexneri
bioconjug
vaccin
invaplex
gener
modul
membran
antigen
gmma
one
critic
strateg
issu
whether
priorit
licensur
approv
etec
vaccin
focu
develop
combin
shigella
like
delay
timelin
vaccin
avail
epidemiolog
data
suggest
intraand
intercountri
diseas
heterogen
like
exist
may
drive
vaccin
prefer
present
optim
data
critic
inform
decisionmak
countri
policymak
reason
develop
deriv
prefer
product
characterist
etec
shigella
vaccin
alon
combin
need
april
plo
releas
collect
global
burden
noroviru
prospect
vaccin
develop
includ
current
estim
global
noroviru
diseas
burden
death
low
resourc
countri
global
econom
burden
billion
recent
molecular
analys
sampl
commun
base
longitudin
birth
cohort
male
studi
suggest
noroviru
common
diarrheal
pathogen
first
year
life
second
common
second
year
life
vaccin
candid
develop
includ
three
strategi
develop
combin
vaccin
enter
pathogen
howev
one
candid
compos
two
vlp
base
gii
noroviru
genotyp
enter
clinic
studi
phase
iib
studi
began
recent
advent
cell
cultur
method
noroviru
facilit
mani
advanc
includ
optim
neutral
assay
enabl
assess
antisera
vaccin
block
bind
divers
genotyp
addit
respons
pdvac
recommend
consid
incorpor
noroviru
surveil
within
global
rotaviru
surveil
network
survey
capabl
capac
repres
global
site
perform
support
pilot
studi
propos
recent
publish
epidemiolog
burden
diseas
data
indic
noroviru
fulfil
pdvac
criterion
unmet
public
health
vaccin
lmic
howev
abil
candid
pipelin
offer
protect
rang
circul
emerg
viral
genotyp
therefor
durat
protect
vaccin
current
unknown
conceiv
vaccin
need
period
reformul
includ
emerg
genotyp
addit
infant
prioriti
target
popul
adult
particularli
elderli
risk
requir
potenti
need
two
vaccin
formul
andor
present
fortun
current
time
develop
noroviru
vaccin
may
offer
efficaci
context
low
middl
incom
countri
proceed
invest
privat
sector
howev
assess
vaccin
programmat
suitabl
applic
prequalif
need
prior
phase
iii
trial
ensur
vaccin
appropri
use
lmic
assum
demonstr
offer
coverag
circul
genotyp
within
lmic
rotaviru
lead
caus
sever
diarrhea
among
children
year
age
worldwid
caus
sever
diarrheal
hospitalis
associ
signific
mortal
latest
mortal
estim
death
introduct
liveattenu
oral
rotaviru
vaccin
rotateq
rotarix
signific
direct
indirect
impact
countri
use
includ
save
live
reduc
hospit
howev
gavielig
lmic
countri
asia
africa
vaccin
effect
lower
protect
efficaci
observ
sever
rotaviru
diarrhea
first
year
life
wane
protect
also
observ
set
lower
protect
rate
second
year
life
comparison
highincom
countri
protect
higher
persist
second
year
life
thu
despit
enorm
success
live
oral
rotaviru
vaccin
sever
challeng
issu
remain
lower
protect
gavielig
lmic
countri
africa
asia
togeth
high
cost
avail
vaccin
despit
overal
accept
safeti
profil
intussuscept
rate
seem
slightli
increas
vaccin
occurr
oral
rotaviru
vaccin
recipi
high
incom
countri
sever
new
oral
liveattenu
vaccin
compos
altern
strain
midto
latestag
clinic
develop
current
guidanc
document
qualiti
safeti
efficaci
oral
live
attenu
rotaviru
vaccin
would
applic
next
gener
oral
liveattenu
vaccin
new
oral
rotaviru
vaccin
rotavac
develop
bbil
vaccin
current
licens
use
children
approv
use
india
vaccin
avail
privat
market
india
stage
roll
public
health
system
plan
four
state
india
anoth
live
rotaviru
vaccin
evalu
randomis
placebo
control
trial
india
niger
effort
underway
develop
nonrepl
rotaviru
vaccin
nrrv
second
gener
rotaviru
vaccin
may
avoid
risk
intussesept
advanc
candid
trival
truncat
rotaviru
genotyp
p
p
p
current
phase
ii
clinic
test
parenter
rout
administr
nrrv
addit
oral
liveattenu
vaccin
develop
pdvac
encourag
ration
target
product
profil
new
candid
clearli
articul
distinguishingadvantag
featur
exist
vaccin
ie
cost
safeti
efficaci
lmic
stabil
breath
protect
etc
potenti
vaccin
candid
includ
combin
emerg
enter
vaccin
clearli
advantag
encourag
explor
combin
ipv
could
consid
clostridium
difficil
lead
caus
healthcareassoci
diarrhoeal
diseas
highincom
countri
strongli
associ
increas
age
frailti
immunodefici
particular
modif
normal
flora
antibiot
use
result
infect
rang
asymptomat
carriag
mild
infect
sever
diarrheal
diseas
complic
includ
pseudomembran
coliti
toxic
megacolon
us
alon
believ
caus
approxim
million
infect
death
current
intervent
includ
antibiot
treatment
use
trigger
relaps
withdraw
data
burden
diseas
lmic
lack
howev
hospit
base
studi
india
thailand
south
korea
suggest
c
difficil
infect
widespread
global
douc
manuscript
prepar
correl
toxin
neutralis
antibodi
human
serum
diseas
protect
antibodi
toxin
associ
protect
acut
diarrhea
whilst
immun
respons
toxin
b
appear
effect
sever
diseas
relaps
toxinmedi
diseas
recapitul
syrian
golden
hamster
standard
preclin
model
demonstr
proof
concept
current
three
vaccin
clinic
develop
toxoid
vaccin
candid
contain
toxin
b
recent
complet
phase
ii
studi
healthi
adult
demonstr
induct
high
level
neutral
antibodi
phase
iii
studi
initi
genet
modifi
detoxifi
whole
cell
vaccin
also
complet
phase
ii
alhough
result
yet
report
phase
vaccin
shown
safe
induc
toxinspecif
neutral
antibodi
sustain
month
third
candid
adjuv
recombin
protein
encod
bind
domain
toxin
result
phase
trial
report
phase
ii
studi
complet
passiv
immun
administr
monoclon
antibodi
also
phase
iii
evalu
pdvac
agre
role
facilit
c
difficil
vaccin
develop
clear
given
lack
data
regard
diseas
burden
lmic
howev
would
use
understand
potenti
effect
vaccin
low
resourc
context
pdvac
rais
possibl
test
exist
sampl
gem
male
studi
presenc
c
difficil
addit
would
help
assess
impact
vaccin
mani
reduc
use
cost
antibiot
consid
valu
proposit
vaccin
decisionmak
h
pylori
highli
motil
gramneg
bacterium
infect
mucu
layer
line
stomach
infect
typic
occur
childhood
although
symptom
clinic
diseas
develop
minor
infect
individu
lifetim
h
pylori
associ
gastriti
caus
sever
patholog
includ
gastric
peptic
duoden
ulcer
diseas
significantli
long
term
infect
result
gastric
adenocarcinoma
ga
later
year
life
ga
case
due
h
pylori
infect
ga
lead
caus
death
due
cancer
global
death
cancer
global
preval
h
pylori
believ
approxim
highest
mortal
rate
east
asia
eastern
europ
rout
transmiss
poorli
characteris
oralor
rout
appear
common
mechan
well
vertic
transmiss
mother
child
untreat
h
pylori
infect
sustain
life
infect
thought
develop
associ
patholog
diagnos
h
pylori
infect
current
treatabl
combin
antimicrobi
therapi
howev
antibiot
resist
increas
patient
countri
current
fail
first
treatment
fail
two
round
therapi
antimicrobi
treatment
offer
protect
reinfect
choic
indic
h
pylori
vaccin
challeng
prophylact
vaccin
would
like
need
given
children
first
year
life
reach
maximum
number
target
group
uninfect
would
need
offer
long
term
protect
demonstr
clinic
benefit
ga
effect
therapeut
vaccin
howev
could
given
almost
age
would
ideal
given
decad
life
prior
peak
ga
develop
typic
occur
year
age
advanc
candid
ureas
toxin
fusion
approach
complet
phase
iii
trial
children
china
demonstr
efficaci
natur
acquisit
infect
howev
protect
appear
wane
year
next
step
vaccin
clear
sever
candid
preclin
develop
one
close
phase
studi
pdvac
conclud
burden
h
pylori
signific
vaccin
abl
protect
infect
suffici
long
durat
protect
would
public
health
benefit
therapeut
candid
current
upstream
develop
role
pdvac
matern
immun
increasingli
consid
strategi
prevent
matern
andor
neonat
diseas
approach
proven
protect
matern
neonat
tetanu
place
decad
recommend
influenza
pertussi
vaccin
pregnant
women
prevent
diseas
mother
newborn
respect
howev
first
time
vaccin
develop
specif
indic
immun
pregnant
women
target
popul
respiratori
syncyti
viru
vaccin
advanc
area
follow
group
b
streptococc
vaccin
sinc
pdvac
meet
special
journal
issu
dedic
issu
regard
matern
immun
vaccin
strategi
publish
great
deal
work
underway
strengthen
matern
immun
platform
due
advanc
stage
rsv
vaccin
monoclon
antibodi
develop
rsv
present
sage
inform
april
rsv
caus
million
episod
lower
respiratori
infect
lri
annual
children
approxim
death
lmic
recent
updat
estim
rsv
acut
sever
lri
commun
base
hospit
diseas
death
publish
rsv
global
epidemiolog
network
rsvgen
earli
addit
pneumonia
etiolog
research
child
health
perch
studi
present
publish
result
etiolog
sever
sever
pneumonia
hospit
infant
children
site
africa
asia
preliminari
data
analys
indic
rsv
lead
pathogen
infant
sever
pneumonia
studi
four
rsv
intervent
strategi
current
develop
matern
immun
enabl
passiv
transfer
matern
antibodi
foetu
utero
birth
earli
infant
passiv
immun
longact
monoclon
antibodi
activ
pediatr
immun
vaccin
elderli
advanc
matern
immun
candid
begun
phase
iii
efficaci
test
late
follow
demonstr
induct
palivizumabcompet
antibodi
measur
elisa
women
childbear
age
pmid
pregnant
women
efficaci
trial
group
sequenti
design
enrol
particip
randomis
placebo
control
trial
across
multipl
site
northern
southern
hemispher
expect
take
year
complet
monoclon
antibodi
develop
prevent
rsv
pediatr
next
advanc
extend
halflif
candid
shown
potent
vitro
current
licens
palivizumab
one
dose
may
offer
protect
month
phase
iib
clinic
studi
infant
born
week
gestat
plan
fda
recent
grant
fasttrack
design
product
sinc
palivizumab
patent
recent
expir
collabor
univers
utrecht
develop
biosimilar
palivizumab
reduc
cost
lmic
market
high
yield
product
novel
financ
plan
estim
price
us
per
child
full
month
dose
seri
first
market
author
expect
late
pediatr
rsv
vaccin
candid
least
advanc
howev
two
adenovirusbas
approach
enter
clinic
sinc
last
pdvac
meet
chimp
adenoviru
chad
candid
current
phase
test
adult
follow
age
deescal
seroposit
ultim
seroneg
infant
also
evalu
heterolog
primeboost
regimen
current
phase
test
adult
number
pediatr
vaccin
candid
develop
laboratori
infecti
diseas
nih
phase
trial
infant
children
note
vaccin
contain
delet
gene
show
evid
diminish
replic
enhanc
immunogen
asymptomat
boost
anamnest
respons
follow
natur
acquir
rsv
infect
pmid
two
vaccin
candid
clinic
develop
elderli
postfus
fbase
adjuv
nanoparticl
phase
iii
efficaci
test
data
expect
earli
pdvac
fulli
support
follow
sage
recommend
call
partner
develop
plan
support
global
policymak
rsv
matern
immun
well
passiv
immun
longact
mab
follow
licensur
particular
area
emphasi
includ
rsv
surveil
determin
season
agestratifi
rsv
diseas
burden
commun
morbid
mortal
especi
africa
southeast
asia
assess
long
term
effect
rsv
intervent
potenti
impact
vaccin
reduc
recurr
wheez
demonstr
would
substanti
increas
costeffect
impact
rsv
prevent
intervent
gener
costeffect
impact
data
sage
also
emphas
need
strengthen
matern
immun
platform
collabor
influenza
tetanu
pertussi
vaccin
commun
along
prepar
potenti
countri
introduct
rsv
vaccin
urgent
need
establish
prequalif
pathway
monoclon
antibodi
current
exist
rsv
vaccin
extend
halflif
monoclon
ab
may
becom
avail
next
year
also
imper
initi
earli
discuss
financ
bodi
align
gavi
vaccin
invest
strategi
vi
avoid
delay
achiev
potenti
major
public
health
impact
rsv
immun
recommend
use
global
gb
remain
lead
caus
sepsi
mening
young
infant
greatest
burden
first
day
life
intrapartum
antibiot
prophylaxi
iap
women
risk
transmit
gb
newborn
effect
reduc
young
infant
gb
diseas
burden
mani
high
incom
countri
iap
uptak
limit
difficult
implement
lmic
immun
pregnant
women
gb
vaccin
repres
altern
pathway
protect
newborn
young
infant
gb
diseas
prevent
gb
colon
transplacent
antibodi
transfer
fetu
utero
pdvac
priorit
gb
encourag
engag
develop
guidanc
develop
pathway
gb
vaccin
includ
develop
ppc
guidanc
document
vaccin
roadmap
april
conven
first
consult
gb
vaccin
develop
focu
gb
matern
immun
develop
program
target
lmic
ultim
goal
reduc
global
newborn
young
infant
death
major
knowledg
gap
diseas
burden
character
identifi
recent
data
suggest
gb
underreport
caus
stillbirth
may
profound
implic
estim
global
public
health
impact
futur
gb
vaccin
relationship
gb
colon
prematur
also
clarifi
diseas
surveil
hic
also
suggest
import
residu
unmet
medic
need
despit
implement
iap
two
major
pharmaceut
compani
current
develop
multival
polysaccharid
conjug
vaccin
base
avail
evid
associ
transplacent
maternalfoet
transfer
antibodi
target
polysaccharid
gb
envelop
acquir
consequ
natur
exposur
reduc
risk
invas
infant
diseas
vaccin
incorpor
five
eleven
describ
gb
serotyp
predict
cover
global
circul
serotyp
risk
serotyp
replac
unknown
altern
approach
target
surfac
express
protein
attempt
confer
broad
protect
across
serotyp
epidemiolog
studi
evalu
role
matern
antibodi
acquir
follow
natur
exposur
determin
whether
protect
threshold
birth
serv
accept
vaccineinduc
correl
protect
addit
epidemiolog
immunolog
data
avail
estim
vaccin
efficaci
invas
gb
diseas
neonat
young
infant
doubl
blind
placebocontrol
vaccin
trial
remain
gold
standard
gener
evid
requir
determin
potenti
public
health
impact
inform
polici
decisionmak
pdvac
endors
consensusbas
priorit
futur
activ
includ
develop
ppc
vaccin
develop
technolog
roadmap
effort
made
rais
awar
burden
gb
diseas
potenti
public
health
valu
gb
vaccin
particularli
countri
lack
local
epidemiolog
data
rsv
effort
must
made
leverag
strengthen
matern
immun
platform
align
vaccin
administ
pregnanc
includ
brighton
collabor
consider
safeti
monitor
global
align
immun
safeti
assess
pregnanc
gaia
antimicrobialresist
infect
current
claim
least
live
year
across
europ
us
alon
amr
affect
mani
hundr
thousand
area
world
european
countri
bloodstream
staphylococcu
aureu
infect
caus
methicillinresist
strain
mrsa
sever
countri
see
resist
rate
closer
emerg
resist
treatment
diseas
tb
malaria
hiv
enorm
impact
lowerincom
set
death
toll
due
amr
infect
africa
predict
approx
per
year
mention
year
almost
million
case
drugresist
tb
report
extrem
costli
treat
mdr
case
cost
treat
drug
sensit
case
xdr
case
expens
estim
approxim
billion
per
year
requir
support
tb
care
control
effort
lmic
significantli
current
invest
tb
vaccin
develop
program
oneil
review
antimicrobi
resist
estim
drugresist
infect
could
claim
million
live
per
year
econom
cost
global
gdp
excess
trillion
sixtyeighth
world
health
assembl
may
global
action
plan
tackl
antimicrobi
resist
includ
antibiot
resist
adopt
goal
ensur
continu
success
treatment
prevent
infecti
diseas
effect
safe
medicin
includ
vaccin
qualityassur
use
respons
way
access
need
amr
global
action
plan
gap
base
work
stream
rang
nation
plan
stewardship
antibiot
encourag
r
develop
new
busi
plan
assess
environment
driver
one
work
stream
focus
vaccin
prevent
amr
gap
workstream
vaccin
prevent
amr
base
three
complementari
approach
increas
use
exist
vaccin
develop
vaccin
high
burden
diseas
current
treat
systemat
antibiot
priorit
develop
vaccin
diseas
antibiot
resist
signific
three
approach
challeng
associ
implement
summaris
increas
use
exist
vaccin
logic
increas
use
exist
vaccin
would
reduc
infect
result
reduc
use
antibiot
alway
clear
vaccin
popul
would
greatest
impact
reduc
antibiot
use
potenti
amr
therefor
priorit
exampl
shown
use
children
result
roughli
reduct
antibioticresist
strain
pneumonia
use
reduc
outpati
antibiot
purchas
lead
suggest
global
pediatr
coverag
pcv
could
prevent
million
day
antibiot
use
children
annual
howev
thought
bulk
pneumonia
antibiot
use
pneumonia
infect
older
adult
would
suggest
demonstr
efficaci
pneumonia
vaccin
reduc
antibiot
use
older
adult
expand
use
vaccin
popul
group
countri
vaccin
polici
may
substanti
impact
reduc
amr
exist
vaccin
could
impact
antibiot
use
includ
pertussi
haemophilu
influenza
neisseria
meningitid
typhoid
well
influenza
although
directli
suscept
antibiot
treatment
result
bacteri
superinfect
account
excess
winterrel
antibiot
prescript
countri
order
ration
evidencebas
polici
expand
use
exist
vaccin
priorit
exercis
need
perform
take
account
diseas
burden
differ
popul
antibiot
use
associ
diseas
burden
evalu
mani
day
antibiot
use
would
avoid
dose
vaccin
administ
exercis
particularli
challeng
sinc
world
antibiot
taken
respons
symptom
rather
identifi
infect
mean
exampl
prevent
salmonella
typhiinduc
infect
vaccin
may
minim
impact
antibiot
use
sever
diarrhea
priorit
exercis
therefor
need
consid
diseas
burden
symptom
burden
proport
burden
due
vaccineprevent
infect
b
develop
vaccin
diseas
consist
treat
antibiot
amr
current
issu
vaccin
could
reduc
antibiot
use
one
exampl
group
streptococcu
ga
ga
directli
associ
antibiot
resist
littl
evid
resist
date
high
diseas
burden
sourc
extens
antibiot
use
addit
thought
vaccin
develop
feasibl
howev
date
signific
effort
industri
possibl
weak
market
assess
sinc
treat
antibiot
treatment
cheap
howev
indirect
cost
antibiot
use
increas
environment
exposur
antibiot
expans
amr
consid
take
cost
account
may
contribut
valu
proposit
develop
use
vaccin
candid
could
includ
group
b
streptococcu
catarhali
nontyp
haemophilu
influenza
respons
otiti
media
anoth
sourc
signific
antibiot
prescript
includ
potenti
impact
reduct
antibiot
use
priorit
candid
vaccin
also
need
consid
technic
feasibl
whether
antibiot
use
appropri
whether
altern
nonantibiot
approach
may
make
vaccin
use
less
attract
exampl
million
case
otiti
media
per
year
year
old
antibiot
treatment
usual
prescrib
could
justifi
develop
vaccin
otiti
media
resolv
new
guidelin
recommend
limit
antibiot
treatment
anoth
exampl
urinari
tract
infect
frequent
elderli
patient
caus
signific
antibiot
use
yet
littl
support
evid
infect
could
effect
reduc
vaccin
priorit
exercis
therefor
requir
vaccin
consid
technic
feasibl
take
account
potenti
amr
impact
therefor
could
contribut
cost
effect
vaccin
develop
achiev
evalu
impact
amr
recommend
includ
review
vaccin
conduct
pdvac
c
third
challeng
approach
develop
vaccin
pathogen
frequent
antibiot
resist
becom
increasingli
difficult
treat
socal
eskap
pathogen
list
includ
staphylococcu
aureu
pseudomona
aeruginosa
klebsiella
pneumonia
well
clostridium
difficil
tuberculosi
numer
challeng
approach
first
although
infect
may
result
signific
morbid
current
global
diseas
burden
mani
infect
remain
rel
low
prophylact
vaccin
entir
popul
would
costeffect
tuberculosi
howev
exampl
signific
diseas
burden
rapidli
expand
multidrug
resist
secondli
mani
infect
associ
age
immun
declin
may
make
immun
intervent
poorli
effect
associ
penetr
medic
intervent
time
avail
induc
protect
immun
respons
may
insuffici
final
despit
signific
effort
make
effect
vaccin
far
proven
difficult
tuberculosi
appear
greatest
global
burden
public
health
impact
tb
vaccin
also
subject
extens
research
amr
gap
activ
area
conduct
ivr
firstli
promot
tb
vaccin
research
develop
facilit
prefer
product
characterist
establish
roadmap
vaccin
use
highlight
impact
vaccin
antibiot
use
antibiot
resist
addit
activ
involv
monitor
state
develop
vaccin
pathogen
becom
antibiot
resist
facilit
develop
ga
ubiquit
human
pathogen
caus
broad
diseas
spectrum
mild
sever
seriou
rheumat
heart
diseas
rhd
rhd
affect
approxim
million
peopl
global
million
experi
heart
failur
estim
die
ga
also
major
caus
invas
diseas
case
fatal
rate
high
incom
countri
high
lmic
milder
end
spectrum
ga
caus
approx
million
case
pharyng
per
year
result
case
treat
broad
spectrum
antibiot
rather
penicillin
case
ga
univers
suscept
extens
use
unnecessari
inappropri
antibiot
increas
likelihood
amr
emerg
antibiot
use
treat
rang
pathogen
previou
human
challeng
studi
well
preclin
anim
model
suggest
feasibl
develop
vaccin
ga
sinc
previou
pdvac
meet
phase
studi
one
candid
initi
adult
two
addit
candid
expect
enter
phase
studi
next
month
despit
encourag
progress
signific
debat
remain
appropri
indic
optim
clinic
endpoint
regulatori
pathway
vaccin
prevent
reduc
rhd
unclear
addit
percept
increas
prescript
penicillin
would
equal
effect
significantli
cost
effect
method
reduc
condit
result
ga
infect
issu
like
major
stumbl
block
incentivis
invest
ga
vaccin
develop
ga
priorit
pdvac
previous
recommend
develop
busi
case
global
market
also
specif
lmic
would
focu
prevent
sever
outcom
resourc
poor
set
despit
signific
effort
difficult
engag
stakehold
activ
recommend
pdvac
conven
consult
decemb
examin
valu
proposit
ga
vaccin
consid
potenti
impact
across
high
incom
lower
incom
set
includ
consider
current
antibiot
treatment
practic
may
increas
amr
well
investig
perceiv
regulatori
obstacl
aureu
bacterium
found
asymptomat
colon
skin
nare
human
host
well
frequent
caus
human
diseas
caus
spectrum
clinic
manifest
vari
sever
commonli
isol
pathogen
skin
softtissu
infect
septic
arthriti
pneumonia
endovascular
infect
osteomyel
catheteroth
foreignbodi
infect
septicaemia
toxic
shock
syndrom
methicillinresist
aureu
mrsa
document
emerg
rapid
increas
rate
sinc
antibiot
first
introduc
hospitalassoci
mrsa
hamrsa
clone
recogn
lead
caus
nosocomi
infect
unit
state
around
world
high
incom
well
lmic
emerg
communityassoci
mrsa
camrsa
past
sever
decad
concern
emerg
highli
resist
vancomycinresist
aureu
vrsa
date
activ
passiv
immun
approach
base
increas
concentr
opson
antibodi
singl
surfac
antigen
fail
demonstr
protect
antigen
variat
multipl
invas
pathway
lack
surrog
protect
present
signific
obstacl
vaccin
develop
follow
failur
singl
antigen
vaccin
approach
develop
effort
focus
multipl
antigen
number
candid
preclin
develop
one
multi
antigen
approach
compris
antigen
includ
two
capsul
polysaccharid
clump
factor
manganes
transport
protein
advanc
current
effort
also
focus
character
immunopatholog
immun
aureu
infect
identifi
new
antigen
target
develop
repres
preclin
model
opsonis
andor
neutralis
immun
respons
measur
date
none
vaccin
candid
develop
contempl
target
popul
indic
preval
lmic
focu
develop
vaccin
protect
lifethreaten
aureu
infect
high
incom
countri
hope
vaccin
would
also
protect
aureu
infect
includ
commonli
encount
skin
soft
tissu
infect
therefor
applic
lmic
context
sinc
pdvac
meet
new
global
health
sector
strategi
sexual
transmit
infect
develop
adopt
member
state
world
health
assembl
within
strateg
framework
sti
vaccin
develop
highlight
key
need
futur
sti
control
addit
global
roadmap
vaccin
sti
updat
includ
special
issu
pipelin
vaccin
publish
vaccin
current
sti
vaccin
candid
undergo
approach
clinic
develop
herp
simplex
viru
hsv
chlamydia
trachomati
discuss
limit
pathogen
hsv
lead
caus
genit
ulcer
diseas
particular
concern
lmic
increas
acquisit
transmiss
hiv
infect
hsv
type
type
diseas
burden
estim
recent
updat
estim
half
billion
peopl
live
genit
hsv
infect
worldwid
pdvac
previous
recommend
improv
global
estim
neonat
herp
burden
gener
assess
avail
data
recent
complet
preliminari
estim
new
case
global
incid
rate
approx
birth
concern
case
fatal
rate
looker
submit
incid
like
underestim
lmic
hsv
infect
rate
highest
poor
healthcar
infrastructur
mean
neonat
herp
case
like
undetect
primari
data
lack
ongo
evalu
hsv
infect
part
child
health
mortal
prevent
surveil
champ
network
help
address
burden
gap
meet
advanc
therapeut
vaccin
candid
highlight
role
type
vaccin
modul
interact
hsv
hiv
acquisit
discuss
import
consider
vaccin
lmic
consider
support
systemat
reviewmetaanalysi
risk
hiv
acquisit
includ
studi
inform
model
potenti
impact
vaccin
hiv
incid
expect
publish
late
review
biolog
mechan
hsvhiv
interact
implic
vaccin
develop
also
draft
pipelin
therapeut
vaccin
remain
robust
candid
clinic
develop
advanc
data
demonstr
signific
reduct
shed
day
genit
lesion
month
respons
posit
data
niaid
form
hsv
work
group
propos
desir
characterist
therapeut
prophylact
vaccin
hsv
includ
indic
prioriti
target
popul
clinic
trial
endpoint
safeti
efficaci
criteria
document
could
form
foundat
consult
process
gener
guidanc
document
prefer
product
characterist
ppc
pdvac
encourag
activ
collabor
support
develop
ppc
hsv
vaccin
chlamydia
trachomati
gramneg
bacterium
infect
genit
ocular
lung
epithelium
includ
three
set
serovar
serovar
ab
b
ba
c
caus
ocular
trachoma
lead
blind
serovar
dk
caus
sexual
transmit
infect
result
urethr
cervic
pelvic
inflammatori
diseas
pid
associ
infertil
ectop
pregnanc
chronic
pelvic
pain
neonat
pneumonia
neonat
conjunct
serovar
caus
lymphogranuloma
venereum
c
trachomati
ascend
upper
genit
tract
caus
pelvic
inflammatori
diseas
pid
turn
lead
longterm
sequela
includ
tubal
factor
infertil
ectop
pregnanc
chronic
pelvic
pain
advers
outcom
chlamydia
includ
preterm
birth
neonat
conjunct
pneumonia
increas
hiv
risk
current
manag
screen
program
high
incom
countri
feasibl
resourc
constrain
set
case
like
never
diagnos
estim
million
new
case
chlamydia
case
among
adolesc
young
adult
global
burden
chlamydiaassoci
pid
infertil
sequela
well
characteris
estim
proport
infertil
presum
associ
genit
infect
eg
fallopian
tube
etiolog
africa
outdat
thought
approx
women
seek
fertil
care
sever
vaccin
candid
current
preclin
develop
subunit
vaccin
base
chlamydi
major
outer
membran
protein
momp
liveattenu
plasmiddefici
approach
advanc
momp
candid
enter
phase
clinic
test
late
phase
studi
live
attenu
candid
commenc
intend
goal
chlamydia
vaccin
decreas
upper
genit
tract
sequela
howev
pid
challeng
use
clinic
endpoint
difficult
definit
diagnos
caus
pid
multifactori
typic
result
c
trachomati
case
chlamydia
vaccin
commun
seek
guidanc
consensu
build
clinic
endpoint
clinic
studi
includ
evalu
potenti
role
biomark
radiolog
measur
upper
tract
ascens
infect
inflamm
damag
improv
global
burden
diseas
data
vaccin
impact
model
long
term
sequela
also
need
defin
invest
case
vaccin
pdvac
commend
progress
toward
first
vaccin
studi
chlamydia
sinc
look
forward
discuss
path
ahead
earli
clinic
data
avail
section
refer
vaccin
licens
approach
licensur
area
world
current
limit
use
outsid
singl
region
instanc
vaccin
may
potenti
offer
broader
public
health
impact
expand
approv
use
geograph
region
pdvac
seek
understand
perspect
regard
one
common
caus
handfootandmouth
diseas
hfmd
sporad
outbreak
occur
global
sinc
first
isol
late
seri
larg
hfmd
epidem
caus
report
asiapacif
region
china
alon
million
case
report
fatal
children
less
year
age
highest
risk
diseas
although
infect
unusu
mild
selflimit
sever
infect
result
neurolog
cardiopulmonari
complic
death
sever
vaccin
candid
develop
state
meet
chines
nation
regulatori
author
licens
two
vaccin
anoth
progress
first
licens
vaccin
develop
institut
medic
biolog
chines
academi
medic
scienc
approv
use
prevent
diseas
month
old
base
phase
iii
studi
demonstr
efficaci
month
sinovac
also
licens
activ
vaccin
support
phase
iii
data
month
old
beij
vigoo
process
licens
inactiv
vaccin
china
three
vaccin
adjuv
aluminum
hydroxid
given
outbreak
occur
area
world
recent
report
spain
discuss
warrant
intern
health
commun
assess
role
chines
vaccin
outbreak
outsid
china
wake
ebola
outbreak
variou
strategi
propos
avoid
crise
reoccur
key
improv
r
prepared
respons
determin
pathogen
like
greatest
threat
creat
consensu
respect
product
develop
strategi
coordin
global
fund
complementari
r
effort
go
forward
tackl
question
request
member
state
conven
broad
global
coalit
develop
r
blueprint
sustain
platform
acceler
r
two
complementari
object
develop
implement
roadmap
r
prepared
known
prioriti
pathogen
enabl
rollout
emerg
r
respons
earli
effici
possibl
main
approach
underpin
improv
prepared
within
r
blueprint
includ
report
meet
summari
consult
initi
work
toward
mer
cov
roadmap
held
decemb
aim
defin
key
basic
appli
research
activ
identifi
prioriti
technolog
capac
support
vaccin
develop
final
understand
financingprocur
opportun
follow
meet
draft
roadmap
develop
underw
public
consult
prior
finalis
public
well
accept
extraordinari
rate
ebola
viru
vaccin
develop
result
unpreced
collabor
coordin
global
vaccin
r
activ
avail
number
candid
vaccin
could
enter
clinic
phase
evalu
face
anoth
pheic
soon
follow
ebola
viru
diseas
evd
outbreak
global
vaccin
commun
ralli
reflect
lesson
learn
experi
west
africa
year
ago
time
respond
evd
emerg
avail
wellcharacteris
preclin
model
robust
data
essenti
compar
evalu
select
candid
move
clinic
studi
novel
recombin
viral
vector
platform
combin
recombin
protein
valid
evd
experi
could
argu
less
riski
develop
vaccin
futur
pathogen
manufactur
feasibl
scaleup
capabl
still
need
confirm
novel
platform
critic
sustain
public
sector
push
pull
invest
mechan
beyond
initi
emerg
respons
phase
need
creat
incentivis
manufactur
engag
long
term
commit
develop
licens
vaccin
may
use
outbreak
emerg
scenario
pdvac
note
target
product
profil
second
gener
ebola
viru
vaccin
develop
like
cover
ebola
zair
ebola
sudan
marburg
filovirus
need
demonstr
longer
durat
protect
tpp
provid
guidanc
who
prefer
minim
accept
criteria
vaccin
area
discuss
clarifi
tpp
includ
minim
accept
criteria
wherea
prefer
product
characterist
specifi
prefer
statu
zika
viru
epidemiolog
understand
pathogenesi
associ
sequela
evolv
rapidli
public
issu
almost
immedi
date
pdvac
role
overse
work
group
develop
target
product
profil
tpp
use
emerg
futur
outbreak
scenario
tpp
made
avail
public
consult
subject
matter
expert
global
regul
develop
manufactur
conven
discuss
regulatori
consider
develop
vaccin
characterist
describ
tpp
finalis
tpp
posit
paper
public
avail
addit
review
statu
vaccin
develop
pathogen
pdvac
consid
number
crosscut
issu
could
better
integr
therefor
facilit
product
develop
effort
vaccin
intervent
addit
signific
morbid
mortal
drive
develop
vaccin
pathogen
vaccin
current
avail
estim
approxim
million
death
per
year
children
vaccin
prevent
diseas
one
reason
strike
immun
gap
cost
logist
challeng
deliveri
vaccin
cost
manufactur
remit
immun
practic
advisori
committe
ipac
provid
strateg
advic
immun
practic
tool
technolog
intend
improv
deliveri
immun
program
countri
level
overse
recent
form
deliveri
technolog
work
group
dtwg
compos
public
health
organ
funder
procur
agenc
well
vaccin
develop
evalu
r
novel
deliveri
technolog
devic
exampl
microarray
patch
compact
prefil
autodis
inject
technolog
cpad
particular
focu
group
develop
evalu
framework
analyz
highlevel
tradeoff
import
variabl
develop
procur
suppli
chain
cost
coverag
efficaci
safeti
order
facilit
invest
decis
product
develop
vaccin
manufactur
global
polici
maker
incountri
decis
maker
procur
agenc
framework
refer
total
system
effect
tse
intent
deliveri
technolog
work
group
offer
platform
discuss
guidanc
regard
vaccin
prefer
lmic
earli
develop
ultim
vaccin
suitabl
programmat
use
dtwg
report
directli
ipac
potenti
overlap
activ
overseen
pdvac
particularli
consider
second
gener
vaccin
new
vaccin
may
develop
altern
present
needl
syring
pdvac
support
dtwg
encourag
continu
commun
vaccin
develop
devicedeliveri
technolog
develop
identifi
potenti
opportun
novel
combin
product
develop
sever
pathogen
area
mab
develop
vaccinelik
intervent
singl
dose
regimen
long
halflif
render
amen
lmic
context
could
offer
signific
public
health
benefit
candid
rsv
rabi
approach
licensur
within
next
year
procedur
prequalif
urgent
need
avoid
delay
implement
gap
recogn
address
scope
pdvac
overlap
sever
research
agenda
gvap
amr
new
deliveri
technolog
develop
consolid
matern
immun
platform
pdvac
research
agenda
need
clearli
commun
pdvac
ivb
strive
wellinform
effort
research
area
help
shape
align
strategi
appropri
futur
pdvac
meet
consid
potenti
overlap
detail
well
pdvac
ivb
facilit
develop
integr
product
develop
approach
sinc
incept
pdvac
review
pipelin
vaccin
develop
statu
differ
pathogen
pdvac
continu
review
new
pathogen
area
candid
progress
clinic
studi
provid
engag
like
facilit
use
vaccin
reduc
diseas
burden
lmic
one
pathogen
cytomegaloviru
cmv
lead
caus
congenit
infect
worldwid
result
infant
develop
perman
sequela
includ
hear
loss
neurodevelopment
disabl
littl
data
cmv
infect
lmic
recent
system
review
suggest
birth
preval
rang
higher
lmic
europ
north
america
sever
clinic
trial
vaccin
candid
ongo
assess
cmv
vaccin
develop
undertaken
pdvac
rsv
tb
hiv
enter
candid
approach
pivot
data
point
understand
data
need
support
earlier
polici
implement
outcom
key
well
understand
potenti
impact
vaccin
within
broader
control
strategi
includ
diagnost
prevent
pathogen
vaccin
impact
model
understand
composit
set
cost
driver
vaccin
deliveri
import
interact
ipac
pq
team
increas
go
forward
strengthen
link
product
develop
programmat
requir
recommend
pdvac
seek
broaden
role
support
develop
valu
proposit
vaccin
pathogen
poorli
defin
busi
case
exampl
ga
hsv
rais
awar
lmic
diseas
burden
requirementsprocedur
access
lmic
market
may
help
incentivis
financ
develop
vaccin
key
consider
may
potenti
vaccin
reduc
emerg
amr
pdvac
recommend
consid
criterion
futur
landscap
analys
ppc
guidanc
document
pdvac
continu
align
activ
prioriti
within
r
blueprint
pdvac
awar
sever
organ
respons
emerg
prepared
process
priorit
r
agenda
common
complementar
pathogen
list
blueprint
arena
pdvac
continu
horizon
scan
role
advoc
commit
product
develop
vaccin
emerg
diseas
progress
robust
preclin
proof
concept
gener
phase
data
minimum
pdvac
strongli
recommend
collabor
group
coordin
advocaci
fund
vaccin
develop
prepar
inevit
futur
emerg
